An oncologist's expert review of a 42-year-old woman diagnosed with KRAS G12C mutated lung adenocarcinoma, providing insights into optimal treatment recommendations based on current evidence and guidelines.
EP. 1: Introduction to KRAS G12C Lung Adenocarcinoma Patient Case
Provide an overview of the patient's presentation, diagnosis, and initial treatment plan.
EP. 2: Evaluating Appropriateness of First-Line Therapy
Assess whether the initial therapy aligned with standard guidelines based on disease stage.
EP. 3: Importance of Molecular Testing in Lung Adenocarcinoma
Discuss the role of molecular profiling and KRAS G12C testing in guiding treatment decisions of this case.
EP. 4: Managing Untreated Brain Metastases
Address the challenges and recommended approaches for managing the patient’s untreated brain metastases.
EP. 5: Sequencing KRAS-Targeted Therapy in G12C Mutated NSCLC
Review evidence on sequencing of KRAS inhibitors after progression on the initial treatment.
EP. 6: KRAS G12C Inhibitor Washout Period
Analyze the appropriate washout period when switching between KRAS inhibitors.
2 Commerce Drive Cranbury, NJ 08512